AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus

Drugs

Volumn 75, Issue 14, 2015, Pages 1679-1686

  Kim, Esther S ^a   Plosker, Greg L ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; PLACEBO; RECOMBINANT HUMAN INSULIN; INSULIN;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DIABETES MELLITUS; DIABETIC PATIENT; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INHALATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POWDER; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SORE THROAT; THERAPY EFFECT; THROAT IRRITATION; WEIGHT GAIN; DIABETES MELLITUS, TYPE 2; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN;

EID: 84942501331     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0472-0     Document Type: Article

References (28)

1. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. 2014. http://www.cdc.gov. Accessed 14 Aug 2015.
2. American Diabetes Association. Standards of medical care in diabetes - 2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97-111.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):S81-90.
4. Centers for Disease Control and Prevention. A snapshot: diabetes in the United States. 2014. http://www.cdc.gov. Accessed 14 Aug 2015.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9.
7. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715-20.
8. Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther. 2011;13(12):1201-6.
9. Rosenstock J, Bergenstal R, DeFronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31(11):2177-82.
10. ® (insulin human) inhalation powder: US prescribing information. 2015. http://www.fda.gov. Accessed 13 Aug 2015.
11. US FDA. FDA briefing information for the April 1, 2014 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2014. http://www.fda.gov. Accessed 14 Aug 2015.
12. ® inhaler [poster]. In: Diabetes technology meeting; 2010.
13. ® insulin inhalation powder administration. Pharm Res. 2011;28(9):2157-64.
14. Steiner S, Pfützner A, Wilson BR, et al. Technosphere/insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110(1):17-21.
15. Angelo R, Rousseau K, Grant M, et al. Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3(3):545-54.
16. Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015. doi: 10.2337/dc15-0075.
17. Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015. doi: 10.2337/dc15-0629.
18. US National Institutes of Health. ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov. Accessed 17 Aug 2015.
19. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244-53.
20. Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12(1):49-55.
21. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14(2):163-73.
22. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733-5.
23. Strain WD, Cos X, Hirst M, et al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105(3):302-12.
24. UK Medicines Information. New drugs online: insulin inhaled. 2015. http://www.ukmi.nhs.uk. Accessed 27 Aug 2015.
25. Mintz ML. Is inhaled insulin a 'game changer'? 2014. http://www.medscape.com. Accessed 14 Aug 2015.
26. Mack GS. Pfizer dumps Exubera. Nature Biotechnol. 2007;25(12):1331-2.
27. US FDA. Exubera (insulin human [rdna origin]) aerosol powder: US prescribing information. 2008. http://www.fda.gov. Accessed 14 Aug 2015.
28. Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2(3):518-29.